Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Notes Payables (2016 - 2019)

Arrowhead Pharmaceuticals (ARWR) has disclosed Notes Payables for 8 consecutive years, with $2.7 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Notes Payables rose 1106.33% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Sep 2019, up 1106.33%, and an annual FY2019 reading of $2.7 million, up 1106.33% over the prior year.
  • Notes Payables was $2.7 million for Q3 2019 at Arrowhead Pharmaceuticals, roughly flat from $2.7 million in the prior quarter.
  • Across five years, Notes Payables topped out at $2.7 million in Q1 2019 and bottomed at $144435.0 in Q2 2016.
  • Average Notes Payables over 4 years is $887358.9, with a median of $214130.0 recorded in 2017.
  • The sharpest move saw Notes Payables rose 7.31% in 2017, then skyrocketed 1149.84% in 2019.
  • Year by year, Notes Payables stood at $197713.0 in 2016, then increased by 7.34% to $212233.0 in 2017, then surged by 983.71% to $2.3 million in 2018, then rose by 17.39% to $2.7 million in 2019.
  • Business Quant data shows Notes Payables for ARWR at $2.7 million in Q3 2019, $2.7 million in Q2 2019, and $2.7 million in Q1 2019.